Comparison of the effects of ANF 99-126 and ANF 103-126 on captopril-induced renin release in man.

What Was Tested

The paper reports a study of Atrial Natriuretic Factor and Captopril, published as a randomized controlled trial.

The aim was to examine the effects of atrial natriuretic factor (ANF) 99-126 and ANF 103-126, an N-terminal shortened analogue of the peptide, on the plasma renin activity response to captopril, an inhibitor of angiotensin-converting enzyme.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and parallel-group.

Because people in this Atrial Natriuretic Factor study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Atrial Natriuretic Factor study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Atrial Natriuretic Factor group a baseline to be compared against.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Plasma renin activity, plasma ANF 99-126 and ANF 103-126 levels, heart rate and blood pressure were measured.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Blood Pressure, Captopril, Depression, Chemical, Diuretics, Peptide Fragments and Renin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Atrial Natriuretic Factor and Captopril.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1991 (Clinical endocrinology), a journal based in England.

More context: the related ANP (Atrial Natriuretic Peptide) library page, all human trials.